Literature DB >> 7234648

Effects of diltiazem-induced calcium blockade upon exercise capacity in effort angina due to chronic coronary artery disease.

R I Low, P Takeda, G Lee, D T Mason, N A Awan, A N DeMaria.   

Abstract

Few data are available regarding the effects of calcium blockade upon exercise tolerance in patients with stable effort angina due to coronary artery disease (CAD). Therefore we compared the effects of the calcium blocking agent, diltiazem (D), to placebo (P) in 12 patients with chronic effort angina and catheterization documented fixed CAD. The 8-week total protocol consisted of a 1-week baseline period followed by the double-blind randomized crossover alternate 1-week administration of P and D in doses of 120, 180, and 240 mg. Maximal exercise tests (MET) were performed at the end of each 1-week period, while rest radionuclide ventriculography (RVG) was obtained during 240 mg D and corresponding crossover P. Resting heart rate decreased from baseline and initial P at D doses of 60 and 240 mg, but not from P during crossover period. No changes were observed at any dose of D either at rest or during MET in systolic blood pressure or rate . pressure double product. D at 240 mg, but not lower doses, increased MET duration (437 vs 490 seconds, p less than 0.01) and time to angina (383 vs 441 seconds, p less than 0.01). Ejection fraction by RVG was greater with D than P (0.54 vs 0.50, p less than 0.05). Thus these data indicate that calcium blockade with diltiazem provides antianginal efficacy by reducing myocardial oxygen demand, and increases exercise tolerance without depression of myocardial performance in effort angina patients with fixed chronic CAD.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7234648     DOI: 10.1016/0002-8703(81)90605-0

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  12 in total

1.  Proceedings of the British Pharmacological Society, British Pharmacology Section. 18-20 April 1990, Sheffield. Abstracts.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

Review 2.  Calcium-channel blockers and anaesthesia.

Authors:  P G Durand; J J Lehot; P Foëx
Journal:  Can J Anaesth       Date:  1991-01       Impact factor: 5.063

3.  Comparison of the antianginal efficacy of four calcium antagonists and propranolol in stable angina pectoris.

Authors:  M Picca; F Azzollini; A Cereda; G Pelosi
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Acute effects of cicletanine in angina pectoris.

Authors:  D L Murdoch; E Henderson; H J Dargie; G T McInnes
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 5.  Diltiazem.

Authors:  B A Britt
Journal:  Can Anaesth Soc J       Date:  1985-01

Review 6.  Diltiazem. A review of its pharmacological properties and therapeutic efficacy.

Authors:  M Chaffman; R N Brogden
Journal:  Drugs       Date:  1985-05       Impact factor: 9.546

7.  Attenuation by diltiazem of arterial baroreflex sensitivity in man.

Authors:  J F Giudicelli; A Berdeaux; A Edouard; F Lhoste; C Richer; C Thuillez; A Jacolot
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 8.  Role of calcium channel blockers in experimental exercise-induced ischemia.

Authors:  E Thaulow; B D Guth; J Ross
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

9.  Antianginal efficacy and safety of controlled-delivery diltiazem QD versus an equivalent dose of immediate-release diltiazem TID.

Authors:  W P Klinke; M Baird; M Juneau; D Waters; W Warnica; Z Lakhani; L Annable; A P Boulet; L Larivière
Journal:  Cardiovasc Drugs Ther       Date:  1995-04       Impact factor: 3.727

10.  Beneficial effects of diltiazem and propranolol, alone and in combination, in patients with stable angina pectoris.

Authors:  J Kenny; P Kiff; J Holmes; D E Jewitt
Journal:  Br Heart J       Date:  1985-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.